You have the commitment to apply medical science. We have the passion to push the boundaries of innovation. Working together, our commitment and passion can lead to millions more lives transformed.

Boston Scientific invites you to booth #1805, Rhythm Theatre #2 and the Advancing Science Technology Suite to experience our entire suite of solutions, as well as the most advanced and least invasive therapies available.

This program is not part of Heart Rhythm 2016 Official Scientific Sessions as planned by the Heart Rhythm Society Scientific Sessions Program Committee. This event is neither sponsored nor endorsed by the Heart Rhythm Society. This event does not qualify for continuing medical education (CME) credit.

© 2016 Boston Scientific Corporation or its affiliates. All rights reserved. All trademarks are property of their respective owners. CRM-378504-AA MAR2016



MAXIMIZING OUTCOMES IN CRT PATIENTS

CRT Response Challenges Occur in a Significant Subset of Patients

This program will review the pre-implant, intra-implant, and post-implant considerations that ultimately impact the outcome of patients that do not respond to resynchronization therapy. Topics for review include: patient selection, device selection, implant techniques, battery longevity, optimal pacing locations, programming strategies to minimize inappropriate shocks, and device diagnostics for health monitoring.

RHYTHM THEATRE #2 Thursday May 5, 2016 9:35–10:30 am

Faculty

Chair: Suneet Mittal, MD, FHRS, The Valley Hospital, Ridgewood, NJ

Joshua Cooper, MD, FHRS,

Temple University Hospital, Philadelphia, PA

Devi Nair, MD,


Cardiac Associates of Northeast Arkansas, Jonesboro, AK

Jagmeet Singh, MD, PhD, FHRS, Mass General Hospital, Boston, MA



IMAGEREADY™ MR-CONDITIONAL PORTFOLIO

Explore the entire portfolio of ImageReady MR-Conditional products available world-wide from Boston Scientific.



EMBLEMTM S-ICD SYSTEM

Effective defibrillation without transvenous leads

Learn about the EMBLEM S-ICD System and the next generation MRI-compatible S-ICD system* technology with AF monitoring.

*Pending FDA approval. Not available for sale in the U.S.



RHYTHMIA™ MAPPING SYSTEM AND BLAZER™ OPEN-IRRIGATED CATHETER

View the world's most advanced 3D mapping system and Total Tip Cooling™ catheter design built on the BLAZER platform.



WATCHMAN™ LAAC DEVICE

Stroke Risk Reduction Alternative

Learn more about WATCHMAN, a first-of-its-kind LAAC device which offers comparable stroke risk reduction and enables non-valvular AF patients to stop taking warfarin.

NAVIGATING THE GREY ZONE IN S-ICD PATIENT SELECTION

RHYTHM THEATRE #2 Thursday May 5, 2016 12:15–1:15 pm

The edges of the patient spectrum for TV-ICD versus S-ICD are defined today by indications and contraindications. Stratification of the larger patient "grey zone" will be explored with consideration for long-term patient survival. S-ICD current and future directions will be illustrated.

Faculty

Chair: Kenneth A. Ellenbogen, M.D. Medical College of Virginia/VCU School of Medicine, Richmond, Virginia

Reinoud E. Knops, M.D., Academic Medical Center,

Amsterdam, Netherlands

Steven P. Kutalek, M.D., Drexel University College of Medicine, Philadelphia, PA

Jeanne E. Poole, M.D., University of Washington - School of Medicine, Seattle, WA